Wang Yueming
General Manager, Beijing AegleStem Cell Technology Co
Wang Yueming holds a master's degree in international pharmaceutical engineering management and an MBA. With 23 years of experience in senior management in pharmaceutical and drug development companies, as well as 5 years of experience in the research and registration of drugs in immunocellular and stem cell enterprises, and in the establishment and management of enterprises.
He has been recognized as an "Overseas High-level Talent", a leading talent in the "Innovation Project", and a leading talent in the "New National Gate" Project of Daxing district in 2022.
Since joining Beijing AegleStem Cell Technology Co in 2020, he has dedicated all his efforts to organizing and promoting the research and drug registration of the company's first drug—human adipose mesenchymal stem cell therapy for systemic sclerosis injection. His goal is to achieve product launch in 2027, bringing hope to patients with rare diseases.